Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution...
Reexamination Certificate
2005-08-11
2008-11-25
Tate, Christopher R (Department: 1655)
Drug, bio-affecting and body treating compositions
Plant material or plant extract of undetermined constitution...
C424S774000
Reexamination Certificate
active
07455860
ABSTRACT:
This invention relates to a dietary supplement which is a phytochemical composition. This composition is capable of controlling inflammatory conditions and preventing and curing cancer in mammals. The composition comprises a synergistic mixture of standardizedBoswelliaextract, salts of glucosamine, and curcuminoids optionally containing bromelain, chondroitin, methylsulphonylmethane, resveratrol, extracts of white Willow and ginger, and quercetin.
REFERENCES:
patent: 6224871 (2001-05-01), Hastings et al.
patent: 6492429 (2002-12-01), Graus et al.
patent: 7112343 (2006-09-01), Shoemake
patent: 2004/0073060 (2004-04-01), Gokaraju et al.
patent: 2004/0086581 (2004-05-01), Jones
patent: 2004/0241256 (2004-12-01), Ehrenpreis et al.
patent: WO-03/074063 (2003-09-01), None
X. Z. Ding et al., “Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer”, Pancreatology, vol. 1, 2001, pp. 291-299. (abstract).
N. Kimmatkar et al., “Efficacy and tolerability ofBoswellia serrataextract in treatment of osteoarthritis of knee—A randomized double blind placedo controlled trial”, Phytomedicine, vol. 10, 2003, pp. 3-7.
I. Gupta et al., “Effects ofBoswellia serratagum resin in patients with bronchial asthma: results of a double-blind, placebo controlled, 6-week clinical study”, European Journal of Medical Research, vol. 3, 1998, pp. 511-514.
H. Gerhardt et al., “Therapy of active Crohn disease withBoswellia serrataextract H 15”, Z Gastroenterol, vol. 39, 2001, pp. 11-17. (abstract).
H. Safayhi et al., “Anti-Inflammatory Actions of Pentacyclic Triterpenes”, Planta Med., vol. 63, 1997, pp. 487-493.
H. Safayhi et al., “Boswellic Acids: Novel, Specific, Nonredox Inhibitors of 5-Lipoxgenase”, Journal of Pharmacology and Experimental Therapeutics, vol. 261, 1992, pp. 1143-1146.
R. S. Pardhy et al., “β-Boswellic Acid, Acetyl-β-boswellic Acid, Acetyl-II-keto-β-boswellic Acid & II-Keto-β-boswellic Acid, Four Pentacyclic Triterpene Acids from the Resin ofBoswellia serrataRoxb”, Indian Journal of Chemistry, vol. 16B, 1978, pp. 176-178.
K. Hostanska et al., “Cytostatic and Apoptosis-inducing Activity of Boswellic Acids Toward Malignant Cell Lines In Vitro”, Anticancer Research, vol. 22, 2002, pp. 2853-2862.
T. Syrovets et al., “Acetyl-Boswellic Acids Are Novel Catalytic Inhibitors of Human Topoisomerases I and IIα”, Molecular Pharmacology, vol. 58, 2000, pp. 71-81.
M. L. Sharma et al., “Immunomodulatory Activity of Boswellic Acids (Pentacyclic Triterpene Acids) fromBoswellia serrata”, Phytotherapy Research, vol. 10, 1996, pp. 107-112.
E. R. Sailer et al., “Acetyl-11-keto-β-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity”, British Journal of Pharmacology, vol. 117, 1996, pp. 615-618.
E. R. Sailer et al., “Characterization of an acetyl-11-keto-β-boswellic acid and arachidonate-biding regulatory site of 5-lipoxygenase using photoaffinity labeling”, Euro. J. Biochem, vol. 256, 1998, pp. 364-368.
T.E. Towheed, “Current status of glucosamine therapy in osteoarthritis,” Arthritis Rheum., vol. 49, 2003, pp. 601-604.
A. L. Vas, “Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthrosis of the knee in out-patients”, Curr. Med. Res. Opin., vol. 8, 1982, pp. 145-149. (abstract).
E. D'Ambrosio et al., “Glucosamine sulphate: a controlled clinical investigation in arthrosis”, Pharmatherapeutica, vol. 2, 1981, pp. 504-508. (abstract).
M. J. Tapadinhas et al., “Oral glucosamine sulphate in the management of arthrosis: report on a multi-centre open investigation in Portugal”, Pharmatherapeutica, vol. 3, 1982 pp. 157-168. (abstract).
C. Natarajan et al., “Curcumin Inhibits Experimental Allergic Encephalomyelitis by Blocking IL-12 Signaling Through Janus Kinase-STAT Pathway in T Lymphocytes”, The Journal of Immunology, vol. 168, 2002, pp. 6506-6513.
R. R. Satoskar et al., “Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation”, Int. J. Clin. Pharmacol. Ther. Toxicol., vol. 24, 1986, pp. 651-654. (abstract).
L. Dalton, “How Curry Combats Cancer”, C&EN, vol. 81, 2003, p. 8.
S. J. Taussig, “The mechanism of the physiological action of bromelain”, Medical Hypotheses, vol. 6, 1980, pp. 99-104. (abstract).
H. Ako et al., “Isolation of a fibrinolysis enzyme activator from commercial bromelain”, Arch. Int. Pharmacodyn. Ther., vol. 254, 1981, pp. 157-167. (abstract).
G.H. Tilwe et al., “Efficacy and tolerability of oral enzyme therapy as compared to diclofenac in active osteoarthritis of the knee joint: an open randomized controlled clinical trial,” Journal of the Association of Physicians of India, vol. 49, 2001, pp. 617-621.
Monograph, “Methylsulfonylmethane (MSM)”, Alternative Medicine Review, vol. 8, 2003, pp. 438-441.
M. A. Beilke et al., “Effects of dimethyl sulfoxide on the oxidative function of human neutrophils”, J. Lab. Clim. Med., vol. 110, 1987, pp. 91-96. (abstract).
D. L. Layman, “Growth inhibitory effects of dimethyl sulfoxide and dimethyl sulfone on vascular smooth muscle and endothelial cells in vitro”, In Vitro Cell Dev. Biol., vol. 23, 1987, pp. 422-428. (abstract).
J. I. Morton et al., “Effects of oral dimethyl sulfoxide and dimethyl sulfone on murine autoimmune lymphoproliferative disease”, Proc. Soc. Exp. Biol. Med., vol. 183, 1986, pp. 227-230. (abstract).
S. J. Childs, “Dimethyl sulfone (DMSO2) in the treatment of interstitial cystitis”, Urol. Clin. North Am., vol. 21, 1994, pp. 85-88. (abstract).
E. Barrager et al., “A multicentered, open-label trial on the safety and efficacy of methylsulfonylmethane in the treatment of seasonal allergic rhinitis”, J. Alterm Compliment Med., vol. 8, 2002, p. 229. (abstract).
P. R. Usha et al., “Randomised, Double-Blind, Parallel, Palacebo-Controlled Study of Oral Glucosamine, Methylsulfonylmethane and their Combination in Osteoarthritis”, Clinical Drug Investigation, vol. 24, 2004, pp. 353-363. (abstract).
D. Bagchi., “Resveratrol and Human Health”, Keats Publishing, Los Angeles, 2000.
M. Maccarrone et al., “Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity”, Eur. J. Biochem., vol. 265, 1999, pp. 27-34.
J. Martinez et al., “Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production”, Biochem. Pharmocol., vol. 59, 2000, pp. 865-870. (abstract).
B. Schmid et al., “Efficacy and tolerability of a standardized willow bark extract in patients with osteoarthritis: randomized placebo-controlled, double blind clinical trial”, Phytother Res., vol. 15, 2001, pp. 344-350. (abstract).
E. Tjendraputra et al., “Effect of ginger constituents and synthetic analogues on cyclooxygenase-2 enzyme in intact cells”, Bioorg. Chem., vol. 29, 2001, pp. 156-163. (abstract).
K. C. Srivastava et al., “Ginger (Zingiber officinale) in rheumatism and musculoskeletal disorders”, Med. Hypotheses, vol. 39, 1992, pp. 342-348. (abstract).
D. Loggia et al., “Anti-inflammatory activity of benzopyrones that are inhibitors of cyclo- and lipo-oxygenase”, Pharmacol. Res. Commun., vol. 20, 1988, pp. 91-94. (abstract).
H. P. Kim et al., “Effects of naturally-occurring flavonoids and biflavonoids on epidermal cyclooxygenase and lipoxygenase from guinea-pigs”, Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 58, 1998, pp. 17-24. (abstract).
C. C. Fox et al., “Comparison of human lung and intestinal mast cells”, J. All
Gokaraju Ganga Raju
Gokaraju Rama Raju
Golakoti Trimurtulu
Gottumukkala Venkata Subbaraju
Davis Deborah A.
Laila Nutraceuticals
Radar Fishman & Grauer PLLC
Tate Christopher R
LandOfFree
Dietary supplement formulation for controlling inflammation... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dietary supplement formulation for controlling inflammation..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dietary supplement formulation for controlling inflammation... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4036414